吉西他滨联合奥沙利铂治疗晚期非小细胞肺癌

目的观察奥沙利铂联合吉西他滨治疗晚期非小细胞肺癌的疗效及毒副反应。方法对46例晚期非小细胞肺癌患者给予奥沙利铂和吉西他滨治疗，21～28d为一个周期，完成2周期治疗后评价疗效。结果全组患者可评价疗效44例，无完全缓解，部分缓解10例，稳定21例，进展13例，总有效率22．7％，疾病控制率70．5％。主要毒性反应为骨髓抑制和恶心呕吐。结论奥沙利铂联合吉西他滨治疗晚期非小细胞肺癌有一定疗效，毒副反应可耐受，生存质量无明显下降。

Oxaliplatin combined with gemcitabine in the treatment of patients with advanced non-small cell lung cancer

Aim Observe the efficacy and toxicity of the combination of oxaliplatin and gemcitabine in the treatment of advanced non- small cell lung cancer（NSCLC）. Methods There were 46 cases of advanced NSCLC patients who were treated with oxaliplatin and gem- citabine every 21 - 28 days. After 2 cycles the efficacy was evaluated. Results There were 44 cases that could be evaluated . No complete response was observed. The overall response rate was 22.7% （7 partial response）and the disease control rate was 70.5%. The main toxicities were myelosuppression and nausea and vomiting. Conclusion The combination of oxaliplatin and gemcitabine is effective and well tolerated in the treatment of advanced NSCLC. The quality of life is little influenced. The regimen can prolong the survival time of some patients.